NextCure
NXTC
51 hedge funds and large institutions have $67.9M invested in NextCure in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 14 closing their positions.
231% more call options, than puts
Call options by funds: $3.83M | Put options by funds: $1.16M
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
6% more capital invested
Capital invested by funds: $64.3M → $67.9M (+$3.62M)
0.36% more ownership
Funds ownership: 3.98% → 4.34% (+0.36%)
14% less funds holding
Funds holding: 59 → 51 (-8)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$3.43M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.47M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.06M |
| 4 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$897K |
| 5 |
Renaissance Technologies
New York
|
+$622K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$953K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$786K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$483K |
| 4 |
AI
Atom Investors
Austin,
Texas
|
-$310K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$303K |
NXTC Hedge Fund Activity: Q2 2022 in Review
51 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q2 2022, worth a combined $67.9M — up 5.6% from $64.3M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of NXTC and 6 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 15 added.
The largest buyer was K2 Principal Fund, opening a new position worth an estimated $3.43M. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $953K sold.
- 51 institutional investors held NextCure (NXTC) as of Q2 2022, down from 59 in Q1 2022.
- Funds reported $67.9M of NextCure stock for Q2 2022, up 5.6% quarter-over-quarter.
- 6 funds opened new NextCure positions in Q2 2022 and 14 closed out, a net change of -8 holders.
- The largest NextCure buyer in Q2 2022 was K2 Principal Fund, an estimated $3.43M added.
- The largest NextCure seller in Q2 2022 was Silverarc Capital Management, an estimated $953K sold.
Based on aggregated 13F filings for Q2 2022.